ClinConnect ClinConnect Logo
Search / Trial NCT06332131

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · Mar 20, 2024

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

Cancer Therapy Related Cardiotoxicity Immune Checkpoint Inhibitor Therapy

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • ≥18 years of age
  • Either diagnosis of breast cancer with plan for treatment according to the Keynote 522 regimen or non-small-cell lung cancer planned for neoadjuvant treatment that includes pembrolizumab
  • Able to provide written informed consent
  • Exclusion Criteria:
  • * Pregnant or breast-feeding:
  • Prior treatment with ICI therapy.
  • Vulnerable patients, including pregnant women and prisoners
  • Absolute Contraindication to rest/vasodilator stress PET/CT

About Abramson Cancer Center At Penn Medicine

The Abramson Cancer Center at Penn Medicine is a leading academic institution dedicated to advancing cancer research, treatment, and prevention. As part of the University of Pennsylvania, the center integrates cutting-edge scientific discovery with comprehensive clinical care, offering patients access to innovative therapies and clinical trials. Renowned for its multidisciplinary approach, the Abramson Cancer Center collaborates with experts across various specialties to deliver personalized treatment plans while fostering a supportive environment for patients and their families. Committed to improving outcomes and quality of life for cancer patients, the center is at the forefront of groundbreaking research initiatives and educational programs aimed at transforming cancer care.

Locations

Philadelphia, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Marielle Scherrer-Crosbie, MD, PhD

Principal Investigator

University of Pennsylvania

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported